The combined use of CSC vaccines with immunomodulators, such as anti-PD-L1 antibodies, can significantly improve the anti-tumor efficiency of CSC-based vaccines and block the immunosuppressive effect of the TME [73, 74]. Here, CD274 is linked to neoplasm.